Medication is sometimes necessary to treat eye conditions and vision problems. Of course, this is highly dependent on the ...

DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...

Faricimab should be readministered with caution in patients who develop mild intraocular inflammation with a previous dose of ...

it is possible that patients with myopic macular degeneration complicated by CNV may benefit from a new ophthalmic frontier of pharmacologic therapy, including intravitreal injections of anti-VEGF ...

At a single academic tertiary referral center, mild intraocular inflammation developed in four eyes following intravitreal ...

However, bevacizumab is not currently licensed for neovascular age-related macular degeneration (nAMD). Our study is the first trial-based economic ... 5 IVAN also compared discontinuous (as-needed) ...

Many people who have age-related macular degeneration don't know it. But ignoring this condition can lead to vision loss that can make it hard to perform everyday tasks. Many people who have ...

About SYFOVRE® (pegcetacoplan injection) SYFOVRE ® (pegcetacoplan injection) is the first-ever approved therapy for geographic atrophy (GA). By targeting C3, SYFOVRE is designed to provide ...

Dame Judi Dench has given an update on her failing eyesight due to macular disease, admitting that she can no longer leave ...

Age-related macular degeneration may cause a gradual reduction in your central vision over time, so you might not recognize AMD at first.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for ...

ONS-5010 (bevacizumab-vikg) was found to be noninferior to ranibizumab for neovascular age-related macular degeneration at week 12.